East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Pembrolizumab
Keytruda
Routinely available
SMC (1239/17)
18/12/2019

Indication

As monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) with a ≥50% tumour proportion score (TPS) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive tum...

As monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) with a ≥50% tumour proportion score (TPS) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive tumour mutations.

Therapeutic Area

Malignant disease and immunosuppression

Status Description

Routinely available in line with national guidance

Formulation

50mg powder for concentrate for solution for infusion and 25mg/mL concentrate for solution for infusion

Comments

December 2019 - Routinely available in line with national guidance. Included on the Additional List, for Specialist Use only.

Link to Advice

1239/17

Advice Published

10/07/2017

SMC Submission Type

Full

SMC Status

Restricted